0LOVVerastem, Inc.
6.850USD-6.83%Mkt Cap: P/E:

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally…

Key Statistics

Company
Market Cap
Enterprise Value561.09M $
Revenue (TTM)87.53M $
Gross Profit76.71M $
Net Income (TTM)-202.70M $
Revenue/Share0.9850 USD
Last Price6.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryGB
SectorTechnology
IndustrySoftware - Application
ISIN
Valuation
P/E (Trailing)
P/E (Forward)
PEG
EV/EBITDA-3.54
EV/Revenue6.41
P/S
P/B12.07
EPS (TTM)-0.41
EPS (Forward)
52W Range
6.8005% of range7.720
52W High7.720 USD
52W Low6.800 USD
Profitability
Gross Margin87.64%
Oper. Margin-81.62%
EBITDA Margin-181.26%
Profit Margin-231.59%
ROE-471.16%
ROA-49.59%
Growth
Revenue Growth1775.40%
Earnings Growth
Cash Flow & Leverage
Operating CF-162.20M $
CapEx (TTM)
FCF Margin-118.17%
FCF Yield
Net Debt-52.02M $
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity168.71
Current Ratio2.25
Quick Ratio2.12
Book Value/Sh0.5520 USD
Cash/Share1.506 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio
Ex-Div Date
Pay Date
Splits
Last Split0.083333:1
Split DateJun 1, 2023
Analyst Consensus
Rating
Target (Mean)
Target Range
# Analysts
Ownership
Shares Out.73.74M
Float70.57M
Insiders0.90%
Institutions110.61%
Technical
SMA 509.963 (-31.2%)
SMA 2008.966 (-23.6%)
Beta0.29
S&P 52W Chg18.16%
Avg Vol (30d)2.67K
Avg Vol (10d)125
Technical Indicators
RSI (14)
MACD
MACD Signal
MACD Hist.
BB Upper
BB Middle
BB Lower
BB Width
ATR (14)
Vol Ratio (20d)